Cargando…

Tumour cell expression of interleukin 6 receptor α is associated with response rates in patients treated with sunitinib for metastatic clear cell renal cell carcinoma

Clear cell renal cell carcinoma (ccRCC) is the most common type of renal cell carcinoma, and anti‐angiogenic treatment is currently first line therapy for metastatic ccRCC (mccRCC). Response rates and duration of response show considerable variation, and adverse events have a major influence on pati...

Descripción completa

Detalles Bibliográficos
Autores principales:	Pilskog, Martin, Bostad, Leif, Edelmann, Reidunn J, Akslen, Lars A, Beisland, Christian, Straume, Oddbjørn
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley and Sons Inc. 2018
Materias:	Original Articles
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5903692/ https://www.ncbi.nlm.nih.gov/pubmed/29665322 http://dx.doi.org/10.1002/cjp2.96

Ejemplares similares

Predictive value of C-reactive protein in patients treated with sunitinib for metastatic clear cell renal cell carcinoma
por: Pilskog, Martin, et al.
Publicado: (2017)

β2‐adrenergic receptor expression in patients receiving bevacizumab therapy for metastatic melanoma
por: Schuster, Cornelia, et al.
Publicado: (2023)

Predictive value of angiogenic proteins in patients with metastatic melanoma treated with bevacizumab monotherapy
por: Schuster, Cornelia, et al.
Publicado: (2018)

Differences in metastatic patterns in relation to time between primary surgery and first relapse from breast cancer suggest synchronized growth of dormant micrometastases
por: Dillekås, Hanna, et al.
Publicado: (2014)

Expression of Heat Shock Protein 27 in Melanoma Metastases Is Associated with Overall Response to Bevacizumab Monotherapy: Analyses of Predictive Markers in a Clinical Phase II Study
por: Schuster, Cornelia, et al.
Publicado: (2016)

AGAP2-AS1 as a prognostic biomarker in low-risk clear cell renal cell carcinoma patients with progressing disease
por: Nakken, Sigrid, et al.
Publicado: (2021)

The safety and efficacy of sunitinib before planned nephrectomy in metastatic clear cell renal cancer
por: Powles, T., et al.
Publicado: (2011)

Dynamic epigenetic changes to VHL occur with sunitinib in metastatic clear cell renal cancer
por: Stewart, Grant D., et al.
Publicado: (2016)

HSP27 Expression as a Novel Predictive Biomarker for Bevacizumab: is it Cost Effective?
por: Seo, Mikyung Kelly, et al.
Publicado: (2020)

HIF pathway and c-Myc as biomarkers for response to sunitinib in metastatic clear-cell renal cell carcinoma
por: Maroto, P, et al.
Publicado: (2017)

Ki-67 expression is superior to mitotic count and novel proliferation markers PHH3, MCM4 and mitosin as a prognostic factor in thick cutaneous melanoma
por: Ladstein, Rita G, et al.
Publicado: (2010)

Sunitinib treatment for patients with clear-cell metastatic renal cell carcinoma: clinical outcomes and plasma angiogenesis markers
por: Kontovinis, Loukas F, et al.
Publicado: (2009)

Metastatic atypical renal tumour with metanephric characteristics treated with Sunitinib
por: Mohammad, H., et al.
Publicado: (2021)

The efficacy and safety of irinotecan cisplatin and mitomycin chemotherapy in sunitinib pre-treated metastatic clear cell renal cancer
por: Powles, Thomas, et al.
Publicado: (2008)

Type 1 plasminogen activator inhibitor (PAI-1) in clear cell renal cell carcinoma (CCRCC) and its impact on angiogenesis, progression and patient survival after radical nephrectomy
por: Zubac, Dragomir P, et al.
Publicado: (2010)

Analysis of Efficacy and Toxicity Profile of First-Line Sunitinib or Pazopanib in Metastatic Clear Cell Renal Cell Carcinoma in the Brazilian Population
por: Isaacsson Velho, Pedro, et al.
Publicado: (2018)

Tumor necrosis is associated with increased alpha(v)beta(3 )integrin expression and poor prognosis in nodular cutaneous melanomas
por: Bachmann, Ingeborg M, et al.
Publicado: (2008)

Clinical Efficacy and Safety of Bevacizumab Monotherapy in Patients with Metastatic Melanoma: Predictive Importance of Induced Early Hypertension
por: Schuster, Cornelia, et al.
Publicado: (2012)

The Biological Context of C-Reactive Protein as a Prognostic Marker in Renal Cell Carcinoma: Studies on the Acute Phase Cytokine Profile
por: Aarstad, Helene Hersvik, et al.
Publicado: (2020)

Organ-specific and tumor-size-dependent responses to sunitinib in clear cell renal cell carcinoma
por: Tsuchiya, Norihiko, et al.
Publicado: (2014)

Role of IL13RA2 in Sunitinib Resistance in Clear Cell Renal Cell Carcinoma
por: Shibasaki, Noboru, et al.
Publicado: (2015)

CXCL7 is a predictive marker of sunitinib efficacy in clear cell renal cell carcinomas
por: Dufies, Maeva, et al.
Publicado: (2017)

Cellular and physical microenvironments regulate the aggressiveness and sunitinib chemosensitivity of clear cell renal cell carcinoma
por: Nagase, Kei, et al.
Publicado: (2021)

Induction of trismus by sunitinib and pazopanib in metastatic renal cell carcinoma
por: Iyer, Ridhima, et al.
Publicado: (2017)

Complete remission of metastatic renal cell carcinoma to the bone with sunitinib
por: Yoshimura, Akihiro, et al.
Publicado: (2020)

Serum levels of the IL-6 family of cytokines predict prognosis in renal cell carcinoma (RCC)
por: Gudbrandsdottir, Gigja, et al.
Publicado: (2020)

Prognostic and predictive impact of stroma cells defined by PDGFRb expression in early breast cancer: results from the randomized SweBCG91RT trial
por: Strell, Carina, et al.
Publicado: (2021)

Dynamic changes of live/apoptotic circulating tumour cells as predictive marker of response to Sunitinib in metastatic renal cancer
por: Rossi, E, et al.
Publicado: (2012)

Real-world evidence on first-line treatment for metastatic renal cell carcinoma with non-clear cell and sarcomatoid histologies: are sunitinib and pazopanib interchangeable?
por: Bonadioa, Renata Colombo, et al.
Publicado: (2019)

Visceral Adiposity as a Significant Predictor of Sunitinib-Induced Dose-Limiting Toxicities and Survival in Patients with Metastatic Clear Cell Renal Cell Carcinoma
por: Park, Jee Soo, et al.
Publicado: (2020)

Post-treatment neutrophil-to-lymphocyte ratio in predicting prognosis in patients with metastatic clear cell renal cell carcinoma receiving sunitinib as first line therapy
por: Park, Yong Hyun, et al.
Publicado: (2014)

Novel potential predictive markers of sunitinib outcomes in long-term responders versus primary refractory patients with metastatic clear-cell renal cell carcinoma
por: Puente, Javier, et al.
Publicado: (2017)

Soluble forms of PD-L1 and PD-1 as prognostic and predictive markers of sunitinib efficacy in patients with metastatic clear cell renal cell carcinoma
por: Montemagno, Christopher, et al.
Publicado: (2020)

Prognostic and predictive significance of VEGF, CD31, and Ang-1 in patients with metastatic clear cell renal cell carcinoma treated with first-line sunitinib
por: Kraljević, Marija, et al.
Publicado: (2023)

Efficacy and safety of sunitinib in elderly patients with metastatic renal cell carcinoma
por: Hutson, T E, et al.
Publicado: (2014)

Buccodental side effects of sunitinib in patients with metastatic renal cell carcinoma
por: Gilabert, M, et al.
Publicado: (2013)

Intolerance to Sunitinib Treatment in Hemodialysis Patients With Metastatic Renal Cell Carcinoma
por: Yildiz, Ibrahim, et al.
Publicado: (2014)

Clinical significance of sunitinib‐associated macrocytosis in metastatic renal cell carcinoma
por: Bourlon, Maria T., et al.
Publicado: (2016)

The role of netrin-1 in metastatic renal cell carcinoma treated with sunitinib
por: Frees, Sebastian, et al.
Publicado: (2018)

Erythema multiforme major induced by sunitinib for metastatic renal cell carcinoma
por: Watanabe, Daisuke, et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_tr2kmntlgvvb87u9v6fmfe9327